Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proton beam therapy + hyperthermia + gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer
jRCTs031220160Phase 2Active, not recruiting
- Sponsor
- University of Tsukuba Hospital
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by University of Tsukuba Hospital. Primary endpoints: Dose-limiting toxicity rate and 2-year survival rate. Started Sep 2022; status: active, not recruiting.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs031220160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220160.